A meta‐analysis, primarily involving reports from China, noted a 3% prevalence rate of underlying chronic liver disease in those with COVID‐19, although it does not provide specific data on the prevalence of HBV and HCV infections. 7  HBV and HCV are chronic infections that are frequently encountered worldwide, and the former is particularly common in China, where the first cases of COVID‐19 were reported. Thus, there has been concern about the impact of SARS‐CoV‐2 infection on the course of HCV and HBV. Thus far, fortunately, COVID‐19 has been reported infrequently in those with HBV and HCV infections in the United States. In a large series of 5700 hospitalized patients with COVID‐19 in the northeastern United States, HBV and HCV infections were encountered in 0.1% and <0.1% of patients, respectively 8  (Table 1). In contrast, a large hospitalized patient series from Wuhan, China, observed that 2.1% (23/1099) of patients were HBV infected and represented 2.4% of nonsevere cases and 0.6% of severe cases. 9  A single‐center retrospective study from China noted that 12.2% (15/123) of patients with COVID‐19 had HBV infection, and a higher percentage with comorbid HBV, relative to HBV‐negative patients, had higher total bilirubin levels, developed a more severe course (46.7% versus 24.1%), and had a higher mortality rate (13.3% versus 2.8%). 10  Zha et al. 11  noted a background HBV prevalence rate of 6.5% (2/31) while reporting on their experience with the use of corticosteroids in COVID‐19; further, they observed delayed SARS‐CoV‐2 clearance in those with HBV infection.